Cancer Center Oncology Medical Group, Inc-East County
Cancer Center Oncology Medical Group, Inc-East County was paid $21.40M by Medicaid between Jan 2018 and Nov 2024, across 38 billing codes. Its largest line is J9299, Injection, nivolumab, 1 mg — 30% of everything it billed.
33Billing provider infoCANCER CENTER ONCOLOGY MEDICAL GROUP, INC-EAST COUNTY
LA MESA, CA 91942
LA MESA, CA 91942
33aNPI1497737183assigned 11/17/2005
33bProvider typeSpecialist
28Total paid$21.40M
24GClaims119,612
24DCodes billed38
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Specialist providers in California
Rank by total paid#3 of 1,230
Median peer was paid$51K
This provider vs. median417×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 15,301 | $2.25M | |
| 2019 | 16,996 | $3.09M | |
| 2020 | 16,987 | $3.33M | |
| 2021 | 21,942 | $6.45M | |
| 2022 | 17,969 | $3.44M | |
| 2023 | 16,972 | $1.52M | |
| 2024incomplete | 13,445 | $1.32M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| J9299 | Injection, nivolumab, 1 mg | 30% | 935 | 654 | $6.42M |
| J1439 | Injection, ferric carboxymaltose, 1 mg | 18% | 4,401 | 2,971 | $3.84M |
| J9271 | Injection, pembrolizumab, 1 mg | 14% | 261 | 211 | $3.10M |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 7.9% | 15,437 | 9,573 | $1.69M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 6.5% | 18,519 | 17,228 | $1.39M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 4.9% | 20,027 | 19,562 | $1.04M |
| J2505 | Injection, pegfilgrastim, 6 mg | 4.1% | 304 | 243 | $874K |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 2.5% | 710 | 544 | $530K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.1% | 6,802 | 4,581 | $442K |
| J2469 | Injection, palonosetron hcl, 25 mcg | 2.0% | 6,803 | 3,532 | $438K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 1.9% | 3,551 | 3,532 | $413K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.4% | 9,415 | 5,209 | $295K |
26 more codes
| J0897 | Injection, denosumab, 1 mg | 1.4% | 194 | $293K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 12,575 | $204K |
| 96417 | <1% | 2,849 | $134K | |
| 96415 | <1% | 1,581 | $49K | |
| 96402 | <1% | 1,366 | $33K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 7,222 | $30K |
| 96401 | <1% | 473 | $28K | |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | <1% | 15 | $28K |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | <1% | 120 | $26K |
| 96367 | <1% | 742 | $21K | |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 411 | $21K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 850 | $18K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 152 | $12K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 119 | $6K |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 99 | $5K |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 2,602 | $5K |
| 99223 | Prolong inpt eval add15 m | <1% | 31 | $4K |
| 99205 | Prolong outpt/office vis | <1% | 26 | $4K |
| J0640 | Injection, leucovorin calcium, per 50 mg | <1% | 23 | $992.44 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 741 | $592.00 |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 148 | $560.53 |
| J9045 | Injection, carboplatin, 50 mg | <1% | 14 | $506.54 |
| J3489 | Injection, zoledronic acid, 1 mg | <1% | 14 | $457.48 |
| 96411 | <1% | 34 | $425.57 | |
| J9190 | Injection, fluorouracil, 500 mg | <1% | 22 | $329.55 |
| 96523 | <1% | 24 | $161.24 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMASON, DEBBIE (OFFICE MANAGER)